Product Pipeline for New Pharmaceutical Drugs
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Pipeline Snapshot as of July 28, 2021
- Discovery Projects
- 29Phase 1
- 40Phase 2
- 23Phase 3
- 8Registration
- Total100
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
PF-07304814 Therapeutic Area: Hospital (Anti-Infectives) Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: SARS-CoV-2 3CL protease inhibitor (IV anti-viral) | COVID-19 Infection | Phase 1 | New Molecular Entity | Small Molecule |
PF-07242813 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: CD1a inhibitor | Atopic Dermatitis (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06835375 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Chemokine Inhibitor | Lupus (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-07054894 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CCR6 Antagonist | Inflammatory Bowel Disease | Phase 1 | New Molecular Entity | Small Molecule |
danuglipron (PF-06882961) + PF-06865571 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Glucagon-like peptide 1 receptor (GLP-1R) Agonist; Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor | Non-Alcoholic Steatohepatitis (NASH) with Liver Fibrosis | Phase 1 | New Molecular Entity | Small Molecule |
PF-06842874 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 4,6 Inhibitor | Pulmonary Arterial Hypertension (ORPHAN - U.S.) | Phase 1 | New Molecular Entity | Small Molecule |
PF-06946860 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Growth Differentiation Factor 15 (GDF15) Monoclonal Antibody | Cachexia (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-07258669 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Melanocortin-4 receptor (MC4R) Antagonist | Anorexia | Phase 1 | New Molecular Entity | Small Molecule |
PF-07081532 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Glucagon-like peptide 1 receptor (GLP-1R) Agonist | Diabetes Mellitus-Type 2 and Obesity | Phase 1 | New Molecular Entity | Small Molecule |
PF-07202954 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor | Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis
Project advanced | Phase 1 | New Molecular Entity | Small Molecule |
PF-06647020 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity | Cancer (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06821497 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: EZH2 Inhibitor | Cancer | Phase 1 | New Molecular Entity | Small Molecule |
PF-06873600 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 2,4,6 Inhibitor | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
PF-06939999 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: protein arginine methyltransferase 5 (PRMT5) Inhibitor | Solid Tumors | Phase 1 | New Molecular Entity | Small Molecule |
PF-06940434 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Integrin alpha-V/beta-8 Antagonist | Solid Tumors (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06952229 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: transforming growth factor, beta receptor 1 (TGFBR1) Inhibitor | Cancer | Phase 1 | New Molecular Entity | Small Molecule |
PF-07062119 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: GUCY2c CD3 Bispecific Antibody | Solid Tumors (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-07104091 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK2 Inhibitor | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
